Traws Pharma (TRAW) Competitors $1.51 -0.11 (-6.79%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.48 -0.03 (-2.32%) As of 08/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. AKTX, MDCX, CLSD, SNYR, MURA, MAAQ, ALXO, CLNN, GBIO, and DYAIShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Akari Therapeutics (AKTX), Medicus Pharma (MDCX), Clearside Biomedical (CLSD), Synergy CHC (SNYR), Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), ALX Oncology (ALXO), Clene (CLNN), Generation Bio (GBIO), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. Its Competitors Akari Therapeutics Medicus Pharma Clearside Biomedical Synergy CHC Mural Oncology Mana Capital Acquisition ALX Oncology Clene Generation Bio Dyadic International Traws Pharma (NASDAQ:TRAW) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation. Does the media refer more to TRAW or AKTX? In the previous week, Traws Pharma had 11 more articles in the media than Akari Therapeutics. MarketBeat recorded 13 mentions for Traws Pharma and 2 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.94 beat Traws Pharma's score of 0.58 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TRAW or AKTX? Traws Pharma has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Which has preferable valuation & earnings, TRAW or AKTX? Akari Therapeutics has lower revenue, but higher earnings than Traws Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$227K37.01-$166.52M$88.830.02Akari TherapeuticsN/AN/A-$19.79MN/AN/A Is TRAW or AKTX more profitable? Traws Pharma has a net margin of 3,028.25% compared to Akari Therapeutics' net margin of 0.00%. Akari Therapeutics' return on equity of -78.03% beat Traws Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma3,028.25% -953.37% 497.97% Akari Therapeutics N/A -78.03%-31.62% Do analysts recommend TRAW or AKTX? Akari Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 395.10%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in TRAW or AKTX? 7.9% of Traws Pharma shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 13.6% of Traws Pharma shares are held by insiders. Comparatively, 38.1% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAkari Therapeutics beats Traws Pharma on 7 of the 13 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.01M$2.75B$5.67B$9.82BDividend YieldN/A1.77%3.79%4.07%P/E Ratio0.0221.8930.5825.12Price / Sales37.01740.48464.45115.80Price / CashN/A177.1637.4059.05Price / Book-0.175.079.096.18Net Income-$166.52M$31.61M$3.25B$264.89M7 Day Performance0.67%25.12%7.32%4.18%1 Month Performance-4.43%3.84%5.42%1.99%1 Year PerformanceN/A10.43%30.66%24.22% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma1.59 of 5 stars$1.51-6.8%N/AN/A$9.01M$227K0.0217Trending NewsEarnings ReportShort Interest ↓AKTXAkari Therapeutics3.1094 of 5 stars$1.00-3.2%$5.00+401.5%-68.4%$33.14MN/A0.009Upcoming EarningsMDCXMedicus Pharma2.111 of 5 stars$2.41+1.3%$23.50+875.1%N/A$32.30MN/A-2.08N/AEarnings ReportAnalyst ForecastAnalyst RevisionCLSDClearside Biomedical2.7939 of 5 stars$0.43+2.8%$4.20+884.3%-59.9%$32.26M$1.66M-1.0430Earnings ReportShort Interest ↑SNYRSynergy CHC4.5107 of 5 stars$3.58+2.0%$10.00+179.3%N/A$32.24M$34.83M0.0040News CoverageEarnings ReportAnalyst RevisionMURAMural Oncology3.1846 of 5 stars$1.78-3.8%$12.00+574.2%-44.1%$31.95MN/A-0.21119MAAQMana Capital AcquisitionN/A$3.88-6.3%N/A+784.2%$31.53MN/A0.001Gap UpALXOALX Oncology2.911 of 5 stars$0.66+12.7%$3.30+399.2%-75.7%$31.33MN/A-0.2740Earnings ReportGap DownCLNNClene3.2429 of 5 stars$3.69-1.3%$40.00+984.0%-25.8%$30.92M$340K-0.91100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGBIOGeneration Bio3.2952 of 5 stars$4.56-0.4%$80.00+1,654.4%-76.2%$30.70M$19.89M-0.42150News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap DownDYAIDyadic International3.3854 of 5 stars$0.98-3.0%$6.00+512.1%-43.3%$30.39M$3.49M-4.907News CoverageEarnings Report Related Companies and Tools Related Companies Akari Therapeutics Competitors Medicus Pharma Competitors Clearside Biomedical Competitors Synergy CHC Competitors Mural Oncology Competitors Mana Capital Acquisition Competitors ALX Oncology Competitors Clene Competitors Generation Bio Competitors Dyadic International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access